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Abstract
Background: The role of infl ammatory and hemodynamic stress biomarkers in heart failure 
(HF) patients treated de novo with beta-blockers has been poorly studied. 
Methods: A total of 86 patients (age 56 ± 9 years, 81 men) with left ventricular ejection fra-
ction (LVEF) < 40% and previously not treated with beta-blockers were initiated on carvedilol. 
At baseline and 12 months later we performed echocardiography, cardiopulmonary exercise 
testing, and determined serum levels of B-type natriuretic peptide (BNP), endothelin-1 (ET-1), 
C-reactive protein (CRP), interleukin-6, and tumor necrosis factor alpha (TNF -a). Patients 
were followed up over a total period of 9 ± 3 years from baseline. 
Results: Increased baseline CRP and its on-treatment decrease were associated with improvement 
of LVEF (est. coeffi cient per one SD: 1.6; 95% CI: –0.05,3.28; p = 0.056, and –1.80; 
–3.43, –0.18; p = 0.030, respectively) and diminishing of LV end-systolic volume index 
[mL/m2] (–6.83; –11.32; –2.34; p = 0.003, and 5.85; 1.23; –10.46; p = 0.014, respecti-
vely). Higher baseline ET-1 and on-treatment increase in TNF-a predicted frequent ad-
missions (> 1) for cardiac complications (odds ratio per one SD: 1.98; 95% CI: 1.09–3.59; 
p = 0.025, and 2.07, 1.12–3.84, p = 0.021, respectively) whereas higher baseline BNP was 
asociated with increased mortality (hazard ratio per one SD: 2.09, 95% CI: 1.26–3.45; 
p = 0.004). 
Conclusions: Serum biomarkers may have different roles in prediction of clinical outcomes 
among HF patients treated de novo with carvedilol. (Cardiol J 2013; 20, 2: 144–151)
Key words: heart failure, beta-blocker, biological markers, natriuretic peptides, 
endothelin-1, C-reactive protein
Introduction
Effective treatment of chronic heart failu-
re (CHF) has become a constant challenge for 
clinicians in the developed countries [1]. One 
of the therapeutic keystones in CHF, along with 
angiotensin-converting enzymes inhibitors (ACEI), 
is use of beta-blockers, which improves both left 
ventricular (LV) function and survival [2]. In recent 
years, increased attention has been focused on 
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lar, we decided to have a 3-month period without 
beta-blockers before starting carvedilol treatment 
to evaluate a net effect of carvedilol on the study 
endpoints. All the patients were informed that we 
abstained from beta-blockers for 3 months and the 
Ethics Committee accepted our rationale for the 
specifi c study design.
Baseline examination and follow-up
The following parameters were assessed at the 
start of the trial and after three and twelve months 
of carvedilol treatment; cardiac dimensions and 
function on echocardiography; mean heart rate at 
24 hour ambulatory ECG monitoring; exercise capaci-
ty on cardiopulmonary stress test (CPX); and serum 
concentrations of BNP, ET-1, CRP, interleukin-6 
(IL-6), and tumor necrosis factor alpha (TNF-a).
The protocol for echocardiographic measu-
rements has been described in detail previously 
[7]. Briefl y, 2D-echocardiography was performed 
to calculate left ventricular end-diastolic and end-
-systolic volumes (LVEDV and LVESV) adjusted 
for body surface (as a respective index value). 
LVEF was calculated using the modifi ed Simpson’s 
method, averaging three consecutive measure-
ments. These assessments are generally accepted 
as quantitative tools for evaluation of drug effects 
on ventricular remodeling in patients with redu-
ced ejection fraction [8]. CPX was performed, as 
various circulating biologically active substances, 
collectively known as plasma biomarkers, and their 
utility in HF prognosis and therapy monitoring 
[3]. Some of them, such as natriuretic peptides, 
have already entered clinical practice, and others, 
such as endothelin-1 (ET-1) or C-reactive protein 
(CRP), are still under evaluation [2, 3]. Hitherto, 
only a few studies have been performed to assess 
the predictive role of biomarkers and their on-
-treatment changes among CHF patients treated 
with beta-blockers, and specifi cally with carvedilol. 
Although carvedilol tends to reduce plasma levels 
of biomarkers such as CRP [4] or B-type natriuretic 
peptide (BNP) [5], the potential clinical implication 
of higher vs. lower initial biomarker levels and their 
responses to treatment have not been satisfactorily 
explored. 
Consequently, we proposed to investigate a se-
lection of infl ammatory and haemodynamic stress 
biomarkers at the initiation and during carvedilol 
treatment in the population of symptomatic CHF 
patients. The aim of this study was to evaluate 
whether recently introduced biomarkers can be 
used in prediction of therapeutic response, risk of 
CHF exacerbation and long-term mortality.
Methods
Study population
The study population consisted of 86 patients 
(81 men, mean age 56 ± 9 years) with CHF who 
met the following inclusion criteria: functional 
capacity according to NYHA class II or III, left 
ventricular ejection fraction (LVEF) < 40%, and 
no beta-blocker treatment for at least 3 months 
before entering the study. Patients were recruited 
in the years 2000–2001.The overall study design is 
shown in Figure 1. We excluded patients who had 
undergone percutaneous transluminal coronary an-
gioplasty (PTCA) or coronary artery bypass grafting 
(CABG) within 3 months; with signifi cant aortic or 
mitral valve defects except functional mitral regur-
gitation related to HF; with glomerular fi ltration 
rate below 60 mL/min; and with acute or chronic 
systemic disorders. All patients were receiving 
ACE (1 patient was on angiotensin receptor blocker 
[ARB]) at baseline and some were also treated with 
diuretics and/or digoxin. Carvedilol was introduced 
and titrated according to the regimen previously 
presented [6], starting with a dose of 3.125 mg twice 
a day for 2 weeks. 
The Ethics Committee of the Jagiellonian 
University accepted the study protocol and all 
patients gave their informed consent. In particu-
Inclusion in the study (86 patients) 2000–01
mean age of 56 years, LVEF < 40%,
NYHA II–III treated with ACEI/ARB
Re−evaluation after 12 months (78 patients)
excluded: 1 heart transplantation, 3 sudden cardiac deaths,
3 beta−blocker intolerance, 1 lost to follow−up
Follow−up period (approx. 10 years) until death or Dec 31, 2010
Phone interviews with patient
or his/her family
Collection of hospital records
(hospital admissions due to
cardiac complications)
Reexamination (incl. ECHO,
CPX, CRP, BNP, ET−1,
TNF− , IL−6)a
Carvedilol treatment
continued
Baseline examination
(incl. ECHO, CPX, CRP,
BNP, ET−1, TNF− , IL−6)a
Initiating and titrating
of carvedilol
Figure 1. The overall study design; abbreviation — see 
the text.
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described in detail previously [6], according to the 
modifi ed Naughton protocol as recommended by 
European Society of Cardiology [9]. Peak oxygen 
consumption expressed in mL/kg/min (VO2 peak) 
and as a percentage of the calculated normal value 
(VO2 peak%N) as well as metabolic equivalents 
(METs) value were recorded [10]. Serum levels 
of neurohormones and inflammatory markers 
were measured in blood drawn from the antecu-
bital vein after 30 min supine rest at fasting state 
in the morning. Measurements were done at the 
Laboratory of Radioligands in Cracow and at the 
Biochemical Laboratory of John Paul II Hospital in 
Cracow. The following commercially available rea-
gents were used in the immunoenzymatic method 
(normal range in parenthesis): Immuno-Biological 
Laboratories (Hamburg) for BNP (up to 100 pg/mL) 
and TNF-a (up to 5.0 pg/mL), Milenia for IL-6 
(up to 5.0 pg/mL) and Cayman for ET-1 (up to 
3.0 pg/mL). Serum CRP was measured enzymati-
cally using monoclonal anti-CRP antibodies labeled 
with horse-radish peroxidase (normal range up 
to 10 mg/L).
The treatment with carvedilol was continued 
after 12 months with a mean dose of 25.8 ± 15.2 mg/
/day. All patients were followed up over a total 
period of 9 ± 3 years from baseline until December 
31, 2010 or death. Information on the vital status of 
participant and the date of death if applicable was 
systematically collected by phone interviews with 
the patient or his/her family according to a special 
questionnaire. In parallel, data on a total number of 
heart-related hospitalizations (CHF exacerbations 
or coronary events) was systematically updated 
before the end of follow-up. 
Statistical analysis
Temporal changes in continuous variables were 
compared using paired T-test. As serum concen-
trations of studied biomarkers were right skewed, 
they were log transformed prior to analyses. 
All biomarkers were scaled to one standard de-
viation (SD) of log-value. A linear regression 
model adjusted for age and gender was applied to 
assess relations between log-transformed base-
line biomarkers levels and their changes during 
follow-up with improvement of LV function and 
exercise capacity parameters (derived from echo-
cardiography [ECHO] and CPX, respectively). 
Similarly, a logistic regression model adjusted 
for age and gender was used to analyze relations 
between biomarkers and frequent hospital ad-
missions due to cardiac complications, defi ned as 
a binary variable of more than one hospitalization 
due to CHF exacerbation or coronary event du-
ring follow-up period. The Kaplan-Maier method 
and multivariate-adjusted (for age and gender) 
Cox regression model were applied to assess 
biomarkers association with long-term mortality. 
All analyses were performed using IBM SPSS sta-
tistical software version 19.0 for Windows (SPSS 
Inc., Chicago, IL). All tests were two-sided and 
p < 0.05 was considered statistically signifi cant.
Results
Baseline characteristics of the study popula-
tion are summarized in Table 1. Twenty-seven 
(31%) patients were in NYHA class II, and the rest 
in NYHA class III. In terms of etiology, 64 (74%) 
patients had ischemic heart disease, of these 61 
(71%) had suffered prior myocardial infarction. 
Seventy-three (85%) patients were at sinus rhythm 
at the start of study. Carvedilol was titrated to the 
mean dose of 25 ± 14 mg/daily during fi rst 3 months 
after initiation of therapy. Mean doses of previously 
prescribed medications did not change signifi-
cantly within 1-year follow-up. Between the 3rd and 
12th month, 1 patient underwent heart transplantation, 
3 sudden cardiac deaths occurred, carvedilol was dis-
continued in 3 patients because of sinus bradycardia 
(n = 2) or worsening of CHF (n = 1), and 1 patient 
was lost to follow-up. Therefore, the fi nal analysis 
at 12 months was done in 78 patients.
The temporal changes in the clinical parameters 
and assessed plasma biomarkers are presented in 
Table 2, Figure 2A, and 2B, respectively. As can 
be seen in Table 3, both baseline CRP (CRP0) and 
its on-treatment decrease (∆CRP) were predic-
tive of LV function improvement (∆LVEF% and 
∆LVESVI). This association was independent of 
baseline LVEF (LVEF0) and LVESVI (LVESVI0). 
After additional adjustment for LVEF0 both CRP0 
and ∆CRP were still associated with improvement 
of LVEF (estimate coefficient per one SD: 1.6; 
95% confi dence interval [95% CI]: –0.05; 3.28; 
p = 0.056, and –1.80; –3.43, –0.18; p = 0.030, 
respectively) as they were in relation to ∆LVESVI
after adjustment for its initial value (–6.83; 
–11.32; –2.34; p = 0.003, and 5.85; 1.23–10.46; 
p = 0.014, respectively). In contrast, controlling for 
LVESVI0 and LVEDVI0 distinctly attenuated rela-
tionship between on-treatment reduction of TNF-a 
and LV parameters (non signifi cant, data not shown), 
whereas trends for ∆BNP, ∆IL-6 and LV function 
improvement were not independent of baseline LV 
function parameters (data not shown). Moreover, as 
can be further noticed in Table 3, there was a weak 
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association of higher baseline ET-1 (ET-10) and its 
on-treatment decrease (∆ET-1) with the improve-
ment of VO2peak, markedly attenuated after adjust-
ment for initial VO2peak value (0.60; –0.24; 1.44; 
p = 0.16, and –0.48; –1.30; 0.34; p = 0.24, respec-
tively).
Data on heart-related hospital admissions 
were available in 73 patients (mean ± SD: 1.9 ± 
± 1.8; range 0–10); of these 13 patients had no 
hospitalization at all, and 25 patients were admit-
ted only once during the follow-up period. Higher 
ET-10 (odds ratio [OR] per one SD: 1.98; 95% 
CI: 1.09–3.59; p = 0.025) and increase in TNF-a 
(∆TNF-a) at 12-month follow-up (2.07; 1.12–3.84; 
p = 0.021) were independent predictors of frequent 
admissions for cardiac complications. 
Mortality data were available in 83 patients; of 
these 33 (38.4%) died after a mean time of 6 years 
(range 1–11 years). In the Cox regression analysis, 
none of baseline clinical parameters significantly 
differed between those patients who died and those 
who survived but there was a trend for association 
between lower LVEF% and higher mortality (hazard 
ratio [HR] per one percent decrease of LVEF, 95% 
CI: 1.04; 0.99–1.10; p = 0.11). Among studied bio-
markers, higher baseline level of BNP (BNP0) was 
a strong predictor of mortality (n = 76, HR per one SD: 
2.09; 1.26–3.45; p = 0.004) but on-treatment change 
in BNP was not associated with mortality (0.86; 0.55–
–1.34; p = 0.51). In parallel, on-treatment increase in 
TNF-α indicated a trend toward higher mortality (HR: 
1.44; 0.97–2.14; p = 0.069). Relationship between BNP 
level on entering the study and long-term mortality 
is illustrated in Figure 3, which shows Kaplan-Maier 
survival curves for study population stratifi ed by mean 
baseline value of BNP (446 pg/mL). Study participants 
in the higher BNP0 stratum demonstrated two-fold 
increased mortality as compared with participants in 
the lower stratum of BNP0 (50% vs. 25%).
Discussion
We report here that cardiovascular plasma bio-
markers may relate to different clinical outcomes in 
a population of HF patients treated with carvedilol. 
Amelioration of echocardiographic LV parameters 
and exercise tolerance during carvedilol treatment 
was expected [11–13] as was also decrease in cir-
culating infl ammatory and vasoactive substances 
[4, 14, 15]. As summarized in Table 4, increased BNP0 
predicted total long-term mortality; whereas incre-
ased ET-10 indicated patients who were at higher 
risk of frequent hospitalizations as did also on-tre-
atment increase in TNF-a. Moreover, higher ET-10 
and its on-treatment decrease tended to be asso-
ciated with improvement of exercise capacity on 
CPX, although not signifi cantly. In parallel, higher 
CRP0 was predictive of LV function improvement as 
Table 1. Baseline characteristics, biomarkers 
concentration and pharmacological treatment 
of study participants (n = 8).
Characteristic Mean ± SD or 
percentage 
(number)
Age [years] 56 ± 9
Gender [%, men] 84 (81)
BMI [kg/m2] 27 ± 4
SBP [mm Hg] 127 ± 15
DBP [mm Hg] 84 ± 8
Heart rate [bpm] 86 ± 18
Hypertension [%] 69 (59)
Diabetes [%] 17 (15)
Hypercholesterolemia [%] 62 (53)
Total cholesterol [mg/dL] 215 ± 44
HDL cholesterol [mg/dL] 42 ± 11
LDL cholesterol [mg/dL] 136 ± 35
Hemoglobin [g/dL] 14 ± 1
Creatinine clearance [mL/min] 102 ± 35
Biomarkers:
CRP [mg/L] 14.4 ± 14.3
Interleukin-6 [pg/mL] 9.4 ± 8.5
TNF-a [pg/mL] 12.2 ± 8.7
BNP [pg/mL] 464 ± 215
Endothelin-1 [pg/mL] 49 ± 95
Pharmacological treatment:
ACE inhibitor 99 (85)
ARB 1 (1)
Loop diuretic 49 (42)
Spironolactone 71 (61)
Digitalis 6 (5)
ASA 77 (66)
Statin 62 (53)
BMI — body-mass index; SBP — systolic blood pressure; 
DBP — diastolic blood pressure; Hypercholesterolemia, total 
serum cholesterol ≥ 200 mg/dL; CRP — C-reactive protein; 
TNF-a — tumor necrosis factor-a; BNP — B-type natriuretic 
peptide; ACE — angiotensin converting enzyme; ARB — 
angiotensin receptor blocker; ASA — acetylsalicylic acid
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was also decrease in this biomarker concentration 
during fi rst 12 months of therapy. So, although the 
total cardiac function and exercise tolerance im-
proved and serum concentrations of the assessed 
plasma biomarkers signifi cantly decreased there 
was a distinct diversity in biomarkers’ predictive 
properties. In concordance with previous reports 
[16–18], baseline BNP level was a strong predictor 
of all-cause mortality but in contrast to them it 
was not prognostic of subsequent cardiovascular 
hospitalizations. Further, on-treatment changes in 
BNP had no role in prediction of mortality, hospi-
talizations, or therapeutic response to carvedilol. 
This observation is important in the light of current 
debate on use of BNP as a therapy monitoring tool 
in CHF. The guidelines admit that such application 
of natriuretic peptides is “less clearly established” 
[2] and that results of previous trials seem contra-
dictory [19, 20]. Endothelin-1, another emerging 
haemodynamic stress biomarker, demonstrated 
association with frequent hospitalizations, but not 
with mortality, which is only partially concordant 
with recent studies [21]. Interestingly, temporal 
changes in TNF-a and not its pretreatment con-
centration were also associated with the risk of 
cardiac exacerbations: patients with increasing 
on-treatment TNF-a level were more likely to be 
hospitalized. The role of TNF-a in deterioration of 
CHF was previously reported [22] and our study 
confi rms these fi ndings. 
Figure 2. A. Changes in inflammatory biomarkers during 12-month therapy with carvedilol; B. Changes in hemody-
namic stress biomarkers during 12-month therapy with carvedilol; CRP — C-reactive protein [mg/L]; TNF-α — tumor 
necrosis factor-a [pg/mL]; IL-6 — interleukin-6 [pg/mL]; BNP — B-type natriuretic peptide [pg/mL]; ET-1 — endothe-
lin-1 [pg/mL]. 
Table 2. Changes in echocardiographic and exercise capacity parameters during treatment with 
carvedilol (n = 78); mean ± SD.
Parameter Baseline At 3 months At 12 months P (0–12 months)
LVEF [%] 27 ± 6 34 ± 8 37 ± 9  < 0.001
LVESVI [mL/m2] 68 ± 27 63 ± 28 55 ± 27 < 0.001
LVEDVI [mL/m2] 97 ± 39 94 ± 35 86 ± 33 0.005
VO2peak [mL/kg/min] 15 ± 5 15 ± 4 16 ± 4 0.10
VO2peak%N 52 ± 16 53 ± 16 57 ± 15 0.04
Tmax [min] 9.9 ± 4.6 11.2 ± 5.1 12.4 ± 4.7 < 0.001
METs 4.3 ± 2.3 5.0 ± 2.4 5.5 ± 2.1 < 0.001
24h-heart rate [/min] 76 ± 11 72 ± 11 72 ± 10 < 0.001
LVEF — left ventricular ejection fraction; LVEDVI — left ventricular end-diastolic volume index; LVESVI — left ventricular end-systolic vo-
lume index; VO2peak — peak oxygen uptake; VO2peak%N — peak oxygen uptake as % of valid normal; Tmax — cardiopulmonary exercise test 
duration; MET — metabolic equivalent; 24h-heart rate — mean heart rate on 24-hour ambulatory ECG
CRP
A B
TNF−a
Baseline
3 months
12 months
IL−6 BNP ET−1
14.5
7.1
5.4
12.2
10.7
5.3
9.4
7.5
5.3
464
399
333
49.3
30.7
25.9
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The most intriguing fi nding in the present 
study was a strong and independent predictive 
role of increased systemic infl ammatory activity, 
as indicated by CRP, on carvedilol-induced impro-
vement of LV function. In fact, CRP was the only 
plasma biomarker to show a consistent relationship 
with on-treatment changes in echocardiographic 
LV parameters. High-sensitivity CRP is an estab-
lished cardiovascular risk factor in general, and for 
development of CHF in particular [23, 24]. Patients 
with CHF show activation of renin–angiotensin–al-
dosterone and the sympathetic nervous systems, 
which may lead to activation of proinfl ammatory 
Figure 3. Kaplan-Maier survival curves for carvedilol-
-treated heart failure patients (n = 76) dichotomized 
by mean initial B-type natriuretic peptide (BNP) value. 
All-cause mortality in the upper stratum (> 446 pg/mL) 
was 2-fold increased as compared to the lower stratum 
(< 446 pg/mL).
Table 4. Potential role of different plasma 
biomarkers in prediction of clinical outcomes 
among carvedilol-treated heart failure patients 
based on the present study.
Plasma 
biomarker
Clinical outcome to predict
CRP0 LV function improvement
∆CRP LV function improvement
ET-10 Hospitalization; Exercise capacity?
∆ET-1 Exercise capacity?
BNP0 Long-term mortality
∆TNF-a Hospitalization; Mortality?
Abbreviations as in Tables 2 and 3
0
0.0
0.2
0.4
0.6
0.8
1.0
20 40 60 80 100 120 140
Follow−up period [months]
Log rank test p = 0.016
BNP > 446 pg/mL
BNP < 446 pg/mL
Cu
m
ul
at
iv
e 
m
or
ta
lit
y
Table 3. Association of log-transformed biomarkers levels at baseline and their on-treatment changes 
(0–12 months) with improvement of echocardiographic and exercise capacity parameters in adjusted 
linear regression model (estimate coefficient; 95% confidence interval). Estimate coefficients are presented 
per one standard deviation of log-transformed biomarker level or its on-treatment change (n = 78).
Biomarker ∆LVEF 
[%]
∆LVESVI 
[mL/m2]
∆LVEDVI 
[mL/m2]
∆VO2peak 
[mL/kg/min]
∆VO2peak %N ∆METs
Log CRP0 1.82; 0.15; 3.49
P = 0.034
–5.96; –10.76; –1.16
P = 0.016
–3.64; –11.81; 4.54
P = 0.38
–0.44; –1.46; 0.59
P = 0.48
–0.76; –4.72; 3.19
P = 0.70
–0.21; –0.67, 0.26
P = 0.38
∆Log CRP –1.85; –3.51; –0.19
P = 0.030
4.28; –0.59; 9.16
P = 0.084
5.65; –2.45; 13.76
P = 0.17
–0.08; –1.14; 0.98
P = 0.88
–0.28; –3.39; 3.96
P = 0.88
–0.01; –0.50, 0.48
P = 0.97
Log IL-60 0.30; –1.40; 2.00
P = 0.73
–0.48; –5.35; 4.39
P = 0.85
–0.66; –8.68; 7.36
P = 0.87
0.21; –0.79; 1.21
P = 0.68
0.87; –2.97; 4.71
P = 0.65
0.26; –0.20; 0.73
P = 0.26
∆Log IL-6 –1.74; –3.57; 0.09
P = 0.061
2.33; –3.07; 7.73
P = 0.39
0.66; –8.32; 9.63
P = 0.89
–0.11; –1.18; 0.96
P = 0.83
0.14; –3.97; 4.26
P = 0.95
–0.13; –0.63; 0.37
P = 0.61
Log TNF-a0 0.87; –0.89; 2.63
P = 0.33
1.78; –3.33; 6.88
P = 0.49
0.79; –7.59; 9.17
P = 0.85
–0.03; –1.04; 0.98
P = 0.96
0.14; –3.73; 4.01
P = 0.94
–0.27; –0.74; 0.21
P = 0.26
∆Log TNF-a 0.06; –1.77; 1.88
P = 0.95
–5.71; –10.63; –0.79
P = 0.024
–8.09; –15.05; –1.14
P = 0.023
0.07; –0.55; 0.69
P = 0.83
0.69; –1.70; 3.07
P = 0.57
0.18; –0.11; 0.47
P = 0.21
Log BNP0 0.30; –1.54, 2.13
P = 0.75
–2.65; –7.73, 2.44
P = 0.30
–1.58; –8.66, 5.51
P = 0.66
–0.26; –1.27, 0.74
P = 0.60
–0.98; –4.78,
P = 0.61
0.15; –0.32; 0.63
P = 0.52
∆Log BNP –1.63; –3.55; 0.30
P = 0.096
5.01; –0.43; 10.45
P = 0.071
4.23; –3.57; 12.02
P = 0.28
–0.18; –1.33; 0.97
P = 0.76
–0.62; –4.97; 3.73
P = 0.78
–0.07; –0.60; 0.46
P = 0.80
Log ET-10 0.65; –1.14; 2.43
P = 0.47
–1.10; –6.28; 4.07
P = 0.67
0.13; –8.19; 8.45
P = 0.98
0.90; –0.11; 1.90
P = 0.080
2.68; –1.21; 6.56
P = 0.17
0.32; –0.16; 0.80
P = 0.19
∆Log ET-1 –1.35; –3.09; 0.39
P = 0.13
–0.08; –5.57; 5.41
P = 0.98
–0.71; –9.52; 8.10
P = 0.87
–0.90; –1.87; 0.07
P = 0.067
–2.70; –6.44; 1.04
P = 0.15
–0.01; –0.48; 0.46
P = 0.96
CRP — C-reactive protein; IL-6 — interleukin-6; TNF-α — tumor necrosis factor-α; BNP — B-type natriuretic peptide; ET-1 — endothelin-1; 
LVEF — left ventricular ejection fraction; LVEDVI — left ventricular end-diastolic volume index; LVESVI — left ventricular end-systolic 
volume index; VO2peak — peak oxygen uptake; VO2peak%N  — peak oxygen uptake as % of valid normal; MET — metabolic equivalent
150 www.cardiologyjournal.org
Cardiology Journal 2013, Vol. 20, No. 2
cytokines but the exact mechanisms coupling CHF 
with systemic infl ammation have not been hitherto 
explained [23]. Based on this study, it seems that 
HF patients with a relatively higher initial level 
of CRP benefi t most from carvedilol, which may 
have a specifi c anti-infl ammatory effect above and 
beyond the well-known antiadrenergic mechanism 
as suggested by previous studies [25]. Moreover, 
the on-treatment CRP reduction paralleled impro-
vement of LV function making CRP an interesting 
potential biomarker for monitoring the therapeutic 
effect of carvedilol treatment. Taken together, in 
the pretreatment phase of carvedilol therapy the 
optimal biomarker selection would include BNP 
for evaluation of mortality risk, ET-1 for progno-
stic assessment of future cardiac exacerbations, 
and TNF-a for indentifying non-responders who 
are at high risk of frequent hospitalizations due 
to HF worsening. Further, CRP may be a valuable 
predictor of LV response both before and under 
the treatment. However, taking into account that 
carvedilol differs from other beta-blockers in its 
vasodilatory [26] and anti-infl ammatory properties, 
these results cannot be extrapolated onto beta-
-blocker class in toto. 
Limitations of the study
The study sample was relatively small and 
only a few women participated in the study. The 
open-label study design might potentially introduce 
a bias, especially in the clinical assessment of the 
patients. However, all the clinical evaluations as 
well as the laboratory measurements were per-
formed in a blinded fashion by independent indivi-
duals. In addition, since beta-blockers are part of 
the standard treatment of patients with CHF and 
reduced LVEF, there was no control group without 
beta-blocker treatment. A signifi cant part of the 
study sample had an ischemic HF etiology and, 
consequently, the role of infl ammatory biomarkers 
(i.e. CRP) may differ in a population of HF patients 
without underlying ischemic heart disease. This 
group was underrepresented in this study and our 
results cannot be extrapolated without reservation 
on non-ischemic HF. Finally, data on smoking sta-
tus were not available and we cannot exclude that 
a residual confounding in relation to infl ammatory 
biomarkers existed due to this factor.
Conclusions
In conclusion, plasma biomarkers may have 
different roles in prediction of clinical outcomes 
among carvedilol-treated symptomatic HF patients. 
Baseline BNP predicts long-term mortality, incre-
ased baseline CRP and its on-treatment decrease 
indicate higher probability of LV improvement, 
whereas higher baseline ET-1 and on-treatment 
increase in TNF-a identify those with higher risk 
of cardiac exacerbations during treatment. More 
studies on larger patients groups are needed to 
verify these fi ndings.
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